Komori
Precision System Science (7707) · PolicyRestated

Becoming a total systems integrator for the biotechnology industry

First written in FY2016. 21 of 24 entries say "Restated". Latest entry: FY2026.

24entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2021-Q2RestatedFY2022-Q1 – FY20232016: 12017: 320172018: 320182019: 320192020: 320202021: 320212022: 320222023: 320232024: 020242025: 120252026: 12026
Same theme, other companies
Transformation into a Comprehensive Systems Integrator for the Biotechnology IndustryA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「Our Group’s corporate philosophy is to contribute to society by continuously creating proprietary core technologies and providing highly accurate testing systems that are easy for anyone to use, thereby contributing to the early detection and prevention of disease and aiming to realize a society in which everyone can live a healthy life true to themselves.」

    The corporate philosophy set out for FY2025 continues to focus on proprietary platform technologies, highly accurate and user-friendly testing systems, and the early detection and prevention of disease.
  2. FY2025ReframedAnnual report

    「Our Group’s corporate philosophy is to contribute to society by continuously creating proprietary core technologies and providing highly accurate testing systems that are easy for anyone to use, thereby contributing to the early detection and prevention of disease and aiming to realize a society in which everyone can live a healthy life true to themselves.」

    The wording of the corporate philosophy shifted from “contributing to society through the PSS Biosystem Network” to explicitly emphasizing proprietary core technologies, highly accurate and easy-to-use testing systems, and the early detection and prevention of disease.
  3. FY2023RestatedAnnual report

    「As our corporate philosophy, our Group has adopted “Contributing to society through the PSS Biosystem Network” and uses the following as a guiding principle for its business: “We will contribute to society by promoting the effective use of biological information relating to genes, proteins and immunity through the provision of highly accurate, user-friendly open systems across a range of biotechnology fields.”」

    The corporate philosophy centered on the PSS Biosystem Network, highly accurate and user-friendly open systems, and the effective use of biological information continues to be disclosed.
  4. FY2023-Q3RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for automatically extracting DNA and RNA (nucleic acids) from specimens such as blood and tissue cells. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on selling reagents for DNA/RNA (nucleic acid) extraction and PCR testing, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The business domain continues to encompass automated DNA/RNA nucleic acid extraction systems, fully automated PCR testing systems, clinical diagnostics, and reagents and consumables.
  5. FY2023-Q2RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes or nucleic acids from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on selling reagents, including those for DNA extraction and PCR testing, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The business domain continues to extend from automated DNA extraction systems to clinical diagnostics through fully automated PCR testing systems and to reagents and consumables.
  6. FY2023-Q1RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes or nucleic acids from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and are selling them to hospitals, testing centers and other providers in the clinical diagnostics field. We have also focused on selling reagents, including those for DNA extraction and PCR testing, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The integrated business domain encompassing automated DNA extraction systems, fully automated PCR testing systems, clinical diagnostics, and reagents and consumables continues to be described.
  7. FY2022-Q3RestatedAnnual report

    「Against this backdrop, in the biotechnology-related industry our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes or nucleic acids from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on the manufacture and sale of reagents, including those for DNA extraction and PCR testing, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The integrated business domain encompassing research instruments, fully automated PCR testing systems for clinical diagnostics, and reagents and consumables continues to be described, centered on automated DNA extraction systems.
  8. FY2022-Q2RestatedAnnual report

    「Against this backdrop, in the biotechnology-related industry our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes or nucleic acids from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on selling reagents, including those for DNA extraction and PCR testing, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The business domain encompassing research instruments, fully automated PCR testing systems, and reagents and consumables continues to be described, centered on automated DNA extraction systems.
  9. FY2022-Q1RestatedAnnual report

    「Against this backdrop, in the biotechnology-related industry our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes or nucleic acids from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on selling reagents, including those for DNA extraction and PCR testing, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The integrated business domain encompassing research instruments, fully automated PCR testing systems for clinical diagnostics, and reagents and consumables, centered on automated DNA extraction systems, was reaffirmed.
  10. FY2021ReframedAnnual report

    「As our corporate philosophy, we have adopted “Contributing to society through the PSS Biosystem Network” and use the following as a guiding principle for our business: “We will contribute to society by promoting the effective use of biological information relating to genes, proteins and immunity through the provision of highly accurate, user-friendly open systems across a range of biotechnology fields.”」

    In addition to the former expression “total systems integrator for the biotechnology industry,” the Group set out the PSS Biosystem Network, highly accurate and user-friendly open systems, and the effective use of biological information as guiding principles for its business.
  11. FY2021-Q2RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes or nucleic acids from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on selling reagents, including those for DNA extraction and PCR testing, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The business domain continues to extend into clinical diagnostics through fully automated PCR testing systems and into DNA extraction and PCR testing reagents and consumables, centered on automated DNA extraction systems.
  12. FY2021-Q1RestatedAnnual report

    「Against this backdrop, in the biotechnology-related industry our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes or nucleic acids from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on selling reagents, including those for DNA extraction and PCR testing, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The business domain continues to encompass clinical diagnostics through fully automated PCR testing systems and reagents and consumables, including those for PCR testing, centered on automated DNA extraction systems.
  13. FY2020RestatedAnnual report

    「Our Group’s corporate philosophy is to contribute to the health and well-being of humanity as a total systems integrator for the biotechnology industry. Through contributing to the development of the global biotechnology industry, we aim to achieve our own medium- to long-term development and growth and contribute to our stakeholders, including shareholders, business partners and employees.」

    The corporate philosophy of becoming a total systems integrator for the biotechnology industry continues to be maintained.
  14. FY2020-Q3RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes or nucleic acids from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated PCR testing systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on the manufacture and sale of reagents, including DNA extraction reagents, and plastic consumables such as reaction vessels, which are consumed when the instruments are used.」

    The business domain centered on automated DNA extraction systems and extending to clinical diagnostics through fully automated PCR testing systems, as well as reagents and consumables, was reaffirmed.
  15. FY2019RestatedAnnual report

    「Our Group’s corporate philosophy is to contribute to the health and well-being of humanity as a total systems integrator for the biotechnology industry. Through contributing to the development of the global biotechnology industry, we aim to achieve our own medium- to long-term development and growth and contribute to our stakeholders, including shareholders, business partners and employees.」

    The corporate philosophy of becoming a total systems integrator for the biotechnology industry continues to be maintained.
  16. FY2019-Q3RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated genetic diagnostic systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on the manufacture and sale of plastic consumables, such as reagents for DNA extraction and reaction vessels, which are consumed when the instruments are used.」

    The business domain continues to extend from automated research instruments centered on automated DNA extraction systems to clinical diagnostic systems, reagents and plastic consumables.
  17. FY2019-Q2RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated genetic diagnostic systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on the manufacture and sale of plastic consumables, such as reagents for DNA extraction and reaction vessels, which are consumed when the instruments are used.」

    The business domain continues to encompass automated instruments for research, clinical diagnostic systems, and reagents and plastic consumables, centered on automated DNA extraction systems.
  18. FY2019-Q1RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated genetic diagnostic systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on the manufacture and sale of plastic consumables, such as reagents for DNA extraction and reaction vessels, which are consumed when the instruments are used.」

    The business domain serving the biotechnology industry, centered on automated DNA extraction systems and extending to clinical diagnostic systems, reagents and plastic consumables, continues to be described.
  19. FY2018RestatedAnnual report

    「Our Group’s corporate philosophy is to contribute to the health and well-being of humanity as a total systems integrator for the biotechnology industry. Through contributing to the development of the global biotechnology industry, we aim to achieve our own medium- to long-term development and growth and contribute to our stakeholders, including shareholders, business partners and employees.」

    The corporate philosophy of becoming a total systems integrator for the biotechnology industry continues to be maintained.
  20. FY2018-Q3RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes from specimens such as blood and tissue cells, including automated DNA extraction systems. We have also developed fully automated genetic diagnostic systems that combine gene extraction technology with amplification and measurement technologies, and have begun selling them to hospitals, testing centers and other providers in the clinical diagnostics field, in addition to the research and development field. We have also focused on the manufacture and sale of plastic consumables, such as reagents for DNA extraction and reaction vessels, which are consumed when the instruments are used.」

    In addition to the research-focused business centered on automated DNA extraction systems, the Group continues to expand into clinical diagnostics through fully automated genetic diagnostic systems and into reagents and plastic consumables.
  21. FY2018-Q1RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes from specimens such as blood and tissue cells, including automated DNA extraction systems.」

    The business domain of providing automated instruments for the biotechnology-related industry, centered on automated DNA extraction systems, was reaffirmed.
  22. FY2017RestatedAnnual report

    「Our Group’s corporate philosophy is to contribute to the health and well-being of humanity as a total systems integrator for the biotechnology industry. Through contributing to the development of the global biotechnology industry, we aim to achieve our own medium- to long-term development and growth and contribute to our stakeholders, including shareholders, business partners and employees.」

    The corporate philosophy of becoming a comprehensive provider of systems for the biotechnology industry continues to be maintained.
  23. FY2017-Q3RestatedAnnual report

    「In the biotechnology-related industry, our Group has developed a range of automated instruments for use in genetic research, centered on automated equipment for extracting genes from specimens such as blood and tissue cells, including automated DNA extraction systems.」

    The Group’s business domain was reaffirmed as the development of automated instruments for the biotechnology-related industry, centered on automated DNA extraction systems.
  24. FY2016First statedAnnual report

    「Our corporate philosophy is to contribute to the health and well-being of humanity as a total systems integrator for the biotechnology industry. Through contributing to the development of the global biotechnology industry, we aim to achieve our own medium- to long-term development and growth and contribute to our stakeholders, including shareholders, business partners and employees.」

    The company’s corporate philosophy is to become a comprehensive provider of systems for the biotechnology industry, rather than a supplier of standalone equipment.
Moved together

"Dependence on Sales to Roche Group and QIAGEN Group" moved the same way as this thread, in the same document, in 2 of its 24 moves.

2★1
  1. ★This thread
  2. 1Dependence on Sales to Roche Group and QIAGEN Group2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Precision System Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Becoming a total systems integrator for the biotechnology industry | Precision System Science Co.,Ltd. (7707) | Komori